Focal articular cartilage defect
Conditions
Interventions
Group A:Mesenchymal stem cells cultured on stents
Group B:Subchondral bone drilling treatment
Sponsors
The 920th Hospital of the PLA Joint Service Support Force
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 55 years; 2. Acute or chronic knee cartilage injury caused by trauma or peeling osteochondrolitis in an area between 2.0 to 10cm2; 3. Before the study began, the subject was willing and able to sign an informed consent form approved by the Ethics Committee; 4. Willing to cooperate closely with the rigorous postoperative rehabilitation procedures developed by doctors; 5. Willing to cooperate with the entire process and to bear the consequences or associated complications, and the corresponding postoperative treatment measures; 6. Judged by the researchers that the subject could understand the clinical study and cooperate with the whole process; 7. The subjects were able to read, express, and understand the study protocol, and could provide feedback in the appropriate language.
Exclusion criteria
Exclusion criteria: 1. Patients were obese with BMI >= 30kg/m2; 2. Type X legs or Type O legs; 3. A known history of immune system disease and causes damage to the joint and meniscus; 4. Kellgren & Lawrence grade III and above arthritis with large meniscus damage; 5. There are serious heart, liver, kidney, and lung insufficiency; 6. Pregnant women or lactating women; 7. Infected with HIV or drug addict; 8. Knee cavity bacterial infection or purulent arthritis; 9. Patients with tissue metabolic disorders, immune disorders, immune disorders, hematopoietic system, endocrine system and other serious primary disorders or mental disorders, such as coagulation dysfunction, serious diabetes, drug abuse, etc.; 10. Poor compliance, such as reluctance or inability to restrict activity, follow medical advice, and failure to follow up on time; 11. Involved in another clinical study within 6 months; 12. Suffered from diseases that the researchers believe could affect their participation in the study, such as mental disorders, alcohol or drug addiction, malignancy, or serious illness; 13. Subjects were accompanied by severe nervous system or musculoskeletal diseases such as myasthenia gravis, dystrophy, cerebral infarction, cerebral palsy, etc.; 14. Subjects could not express, read, express and understand the study protocol and could provide feedback in the appropriate language. 15. Subjects had other diseases with a life expectancy of less than 2 years; 16. The subject was participating in other clinical trials and did not reach the endpoint; 17. Other patients who were not suitable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Affected limb X line, MRI; | — |
Countries
China
Contacts
Public ContactTan Hongbo
The 920th Hospital of the PLA Joint Service Support Force
Outcome results
None listed